Research summary, original research, 2016

Radiation Exposure during Percutaneous Transluminal Angioplasty for Symptomatic Peripheral Arterial Disease

Sigterman TA, Bolt LJ, Snoeijs MG, Krasznai AG, Heijboer R, Schurink GW, et al.. Annals of vascular surgery. 2016

Read the original paper

In plain language

In 951 patients treated with peripheral endovascular procedures, aortoiliac interventions gave the highest patient dose despite shorter fluoroscopy times. Staff dose was not measured, but higher-dose procedure types may indicate where the fluoroscopy team needs closer protection.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients
Size
n = 951 patients
Summary based on
the abstract

What it found

  • Mean patient dose area product across all peripheral endovascular interventions was 108 Gy·cm2 with mean fluoroscopy time of 13 minutes.

    Key figures: Dose-area product (DAP) 108 ± 88 Gy × cm(2); fluoroscopy time 13 ± 12 min

  • Aortoiliac procedures had higher DAP than femoral, below-knee and multilevel procedures.

    Key figures: 142 ± 103 vs 58 ± 73, 45 ± 51, 83 ± 90 Gy × cm(2); P < 0.001

  • Peak skin dose was highest for aortoiliac procedures.

    Key figures: 0.99 ± 0.54 Gy vs 0.55, 0.48, 0.68 Gy; P < 0.001

  • Aortoiliac interventions had shorter fluoroscopy time than other locations despite higher dose, so fluoroscopy time is a poor proxy for dose.

    Key figures: 10 ± 15 min vs 15, 19, 23 min; P < 0.001

Limits to keep in mind

Single-center observational study measuring patient dose metrics only; no staff dosimetry was reported, and the country and staff roles are not stated in the abstract.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.